DALLAS, June 8 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC (OTC Bulletin Board: ACCPE - News) today announced commencement of the first company- sponsored phase II clinical study of ProLindac(TM), a novel DACH platinum- polymer prodrug. The study is being conducted in Europe, in ovarian cancer patients that have relapsed after first line platinum therapy. The first patient was dosed with the study medication in France. The open-label trial is being managed by Cvitkovic and Associates (CAC), a leading CRO with a specialty in platinum drugs, and will accrue approximately 40 patients.
